NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease

Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.

Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.

Founded in 2014 and funded by a £12m investment from Syncona Partners, NightstaRx is a company focused on therapies for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip